Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
GEP-NET
combination therapy
immunotherapy
thymoquinone
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
21 11 2022
21 11 2022
Historique:
received:
11
10
2022
revised:
07
11
2022
accepted:
12
11
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
Neuroendocrine neoplasms (NENs) are a heterogeneous group of cancers that had a significant increase in annual incidence in the last decade. They can be divided into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Poorly differentiated NECs are aggressive forms of cancers with limited therapeutic options. The first line treatment of metastatic poorly differentiated NECs is similar to small cell lung cancer, with cytotoxic chemotherapy (etoposide plus platinum). Patients who progress have limited therapeutic options and poor overall survival, calling for other novel agents to combat this deadly disease. Therefore, in this article, we summarized the effects of a novel component, Thymoquinone (TQ, C10H12O2), which is the main bioactive component of the black seed ( We report the effect of TQ plus dual immune checkpoint inhibitors (nivolumab plus ipilimumab) in four patients with poorly differentiated gastrointestinal Ep-NEC and MiNEN who progressed on cytotoxic chemotherapy. This is the first case series to report the clinical activity of TQ plus dual immune checkpoint inhibitors (nivolumab plus ipilimumab) in patients with refractory metastatic EP-NEC. The four patients showed benefits with the combined regimen TQ plus dual ICPIs with durable response and exceeded the two years of progression-free survival. None of the four patients experienced significant toxicity, and all of them showed improvement in quality of life. The reported clinical courses suggest that combined TQ plus ICPIs is a potential promising regimen for refractory EP-NEC and MiNEN that deserves further prospective investigation.
Sections du résumé
BACKGROUND
Neuroendocrine neoplasms (NENs) are a heterogeneous group of cancers that had a significant increase in annual incidence in the last decade. They can be divided into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Poorly differentiated NECs are aggressive forms of cancers with limited therapeutic options. The first line treatment of metastatic poorly differentiated NECs is similar to small cell lung cancer, with cytotoxic chemotherapy (etoposide plus platinum). Patients who progress have limited therapeutic options and poor overall survival, calling for other novel agents to combat this deadly disease. Therefore, in this article, we summarized the effects of a novel component, Thymoquinone (TQ, C10H12O2), which is the main bioactive component of the black seed (
METHODS
We report the effect of TQ plus dual immune checkpoint inhibitors (nivolumab plus ipilimumab) in four patients with poorly differentiated gastrointestinal Ep-NEC and MiNEN who progressed on cytotoxic chemotherapy.
RESULTS
This is the first case series to report the clinical activity of TQ plus dual immune checkpoint inhibitors (nivolumab plus ipilimumab) in patients with refractory metastatic EP-NEC. The four patients showed benefits with the combined regimen TQ plus dual ICPIs with durable response and exceeded the two years of progression-free survival. None of the four patients experienced significant toxicity, and all of them showed improvement in quality of life.
CONCLUSION
The reported clinical courses suggest that combined TQ plus ICPIs is a potential promising regimen for refractory EP-NEC and MiNEN that deserves further prospective investigation.
Identifiants
pubmed: 36421360
pii: curroncol29110707
doi: 10.3390/curroncol29110707
pmc: PMC9689659
doi:
Substances chimiques
thymoquinone
O60IE26NUF
Nivolumab
31YO63LBSN
Ipilimumab
0
Immune Checkpoint Inhibitors
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
9018-9030Références
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
J Oncol. 2012;2012:951724
pubmed: 22481935
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Gastrointest Cancer Res. 2008 May;2(3):113-25
pubmed: 19259290
World J Gastroenterol. 2011 Jan 14;17(2):219-25
pubmed: 21245995
Anticancer Res. 2009 Mar;29(3):881-8
pubmed: 19414323
J Gastrointest Cancer. 2015 Jun;46(2):166-9
pubmed: 25662891
J Ethnopharmacol. 2010 Sep 15;131(2):268-75
pubmed: 20600757
Anticancer Res. 2011 Mar;31(3):975-8
pubmed: 21498724
Oncol Rep. 2014 Aug;32(2):821-8
pubmed: 24890449
Int J Oncol. 2003 Jan;22(1):107-13
pubmed: 12469192
Mol Biol Cell. 2005 Sep;16(9):4153-62
pubmed: 15987743
Mol Cell Biochem. 2014 Apr;389(1-2):85-98
pubmed: 24399465
Mol Cancer. 2014 Aug 29;13:201
pubmed: 25174975
Int J Oncol. 2004 Oct;25(4):857-66
pubmed: 15375533
Cornea. 2007 Jul;26(6):715-9
pubmed: 17592323
Antioxidants (Basel). 2019 Feb 25;8(2):
pubmed: 30823525
Ann Gastroenterol. 2013;26(1):29-36
pubmed: 24714698
Indian J Physiol Pharmacol. 2010 Oct-Dec;54(4):344-54
pubmed: 21675032
Oncol Rep. 2014 May;31(5):2063-70
pubmed: 24603952
J Immunotoxicol. 2008 Jul;5(3):279-85
pubmed: 18830888
Cell Cycle. 2009 Apr 15;8(8):1168-75
pubmed: 19282669
Adv Prev Med. 2016;2016:1407840
pubmed: 28105374
Br J Biomed Sci. 2011;68(3):131-7
pubmed: 21950205
Am J Pathol. 2006 Nov;169(5):1875-85
pubmed: 17071608
Endocr Rev. 2019 Apr 1;40(2):506-536
pubmed: 30657883
World J Gastroenterol. 2016 Apr 28;22(16):4149-59
pubmed: 27122665
Mol Cancer. 2013 May 13;12(1):41
pubmed: 23668310
Clin Cancer Res. 2020 Sep 1;26(17):4454-4459
pubmed: 32532787
J Clin Lipidol. 2016 Sep-Oct;10(5):1203-11
pubmed: 27678438
Clin Cancer Res. 2013 Jun 1;19(11):2842-9
pubmed: 23459719
Pathogens. 2022 May 07;11(5):
pubmed: 35631072
ESMO Open. 2022 Feb;7(1):100364
pubmed: 34973511
Int Immunopharmacol. 2015 Sep;28(1):295-304
pubmed: 26117430
Front Pharmacol. 2020 Sep 15;11:555283
pubmed: 33041795
Br J Cancer. 1999 Dec;81(8):1351-5
pubmed: 10604732
Mol Cancer Ther. 2008 Jul;7(7):1789-96
pubmed: 18644991
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Jpn J Clin Oncol. 2010 Apr;40(4):313-8
pubmed: 20047862
Clin Cancer Res. 2020 May 15;26(10):2290-2296
pubmed: 31969335
Mol Cancer Ther. 2010 May;9(5):1419-31
pubmed: 20423995
Clin Endocrinol (Oxf). 2005 Apr;62(4):434-43
pubmed: 15807874
J Clin Oncol. 2020 Apr 10;38(11):1154-1163
pubmed: 31961766
Cell Commun Signal. 2020 Jul 17;18(1):114
pubmed: 32680529